These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 8631036)
41. Immunotoxins: status and prospects. Spooner RA; Lord JM Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624 [TBL] [Abstract][Full Text] [Related]
42. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]
43. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Fulton RJ; Uhr JW; Vitetta ES Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547 [TBL] [Abstract][Full Text] [Related]
44. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030 [TBL] [Abstract][Full Text] [Related]
45. Immunotoxin therapy: prospects for the future. Corliss J J Natl Cancer Inst; 1989 Dec; 81(24):1862-3. PubMed ID: 2593161 [No Abstract] [Full Text] [Related]
46. Therapeutic potential of anticancer immunotoxins. Choudhary S; Mathew M; Verma RS Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052 [TBL] [Abstract][Full Text] [Related]
47. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Keppler-Hafkemeyer A; Kreitman RJ; Pastan I Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457 [TBL] [Abstract][Full Text] [Related]
48. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
57. Monoclonal antibodies and immunoconjugates for cancer treatment. Baldwin RW; Byers VS; Pimm MV Cancer Chemother Biol Response Modif; 1988; 10():397-415. PubMed ID: 3079393 [No Abstract] [Full Text] [Related]
58. Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. Zovickian J; Youle RJ J Neurosurg; 1988 May; 68(5):767-74. PubMed ID: 3258632 [TBL] [Abstract][Full Text] [Related]
59. Vascular targeting--a new approach to the therapy of solid tumors. Burrows FJ; Thorpe PE Pharmacol Ther; 1994 Oct; 64(1):155-74. PubMed ID: 7846113 [TBL] [Abstract][Full Text] [Related]
60. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]